| [1] |
DENG Qingqing, YAO Qingqing, HU Tao, YANG Jiale, BIAN Yicong, MIAO Liyan.
Risk Factors for Liver Injury Induced by Anaplastic Lymphoma Kinase Inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2026, 23(2): 162-166.
|
| [2] |
YE Ling, XU Rui, RUAN Cong, QIAN Jiajia, HU Weiqiong, WANG Qiru, LIU Jiyong, LI Gang.
Advances in Medications for Breast Cancer Leptomeningeal Metastases
[J]. Chinese Journal of Pharmacovigilance, 2026, 23(2): 229-234.
|
| [3] |
SI Fuguo, CUI Jia, CHENG Jun, ZHU Yulin, DAI Biao.
One Case of Toxic Epidermal Necrolysis Caused by Moxifloxacin Hydrochloride and Sodium Chloride Injection
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(11): 1307-1309.
|
| [4] |
LIU Hong, WANG Qian, CHENG Yongjing, CHEN Yingjuan.
One Case of Acute Drug-Induced Liver Injury Caused by Cyclophosphamide for Injection in a Patient with Relapsing Polychondritis
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(10): 1162-1164.
|
| [5] |
YANG Yifan, YANG Yanwei, ZHANG Di, XIE Yin, ZHANG Yong, CHEN Xulin, GAO Sutao, GENG Xingchao, QU Zhe.
Quality Control and Test Methods of Human Induced Pluripotent Stem Cells
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 728-734.
|
| [6] |
REN Yuke, JIANG Hua, LI Lulu, LI Shuangxing, HUO Guitao, YANG Yanwei, ZHANG Di, HUANG Ying, GENG Xingchao, LIN Zhi, QU Zhe.
Research Advances in the Pathogenesis of Cytokine Release Syndrome Induced by CAR-T Cell Therapy
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 735-741.
|
| [7] |
REN Yuke, QU Zhe, LAI Zixuan, ZHANG Di, ZHAO Yongtian, YANG Yanwei, LI Shuangxing, HUO Guitao, ZHOU Xiaobing, LIN Zhi, GENG Xingchao.
Pharmacodynamic Evaluation of CAR-T Cell Products Based on Deep Learning Convolutional Neural Network Recognition
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 742-748.
|
| [8] |
TANG Jiong, ZENG Yuqi.
One Case of Oculomotor Paralysis Caused by Sugemalimab Injection
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 812-814.
|
| [9] |
ZHONG Xinru, YANG Deying, GUAN Tangming, CHEN Ju, JIANG Dongbo.
Research Progress in Adverse Reactions Caused by Obinutuzumab in the Treatment of Follicular Lymphoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 831-835.
|
| [10] |
GAO Caiyun, WANG Boyuan, GAO Xiaojie.
Research Progress in Correlations between SGLT2 Inhibitors and Malignant Tumors
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 836-840.
|
| [11] |
ZHANG Yunhui, CHEN Haoyun, ZHONG Luhua, FANG Caifu, HUANG Huanjun, GUO Chenchen, DONG Xinyi, SHI Feng, LIANG Weiting.
159 Cases of Adverse Reactions to Immune Checkpoint Inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 442-446.
|
| [12] |
CHEN Lingbin, HUANG Zhixiong, ZHENG Cailin, WU Jinneng, CHEN Zhou.
Adverse Event Signals for Osimertinib-Induced Muscle Toxicity Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 447-451.
|
| [13] |
LIU Yalan, LIU Yanxiang, CHEN Peng.
One Case of Vitiligo Caused by Sintilimab Injection in a Patient with Advanced Long-Term Survival Lung Adenocarcinoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 460-462.
|
| [14] |
CHEN Qi, ZHANG Mingqiang, GUO Jun.
One Case of Interstitial Pneumonia Caused by Imatinib Mesylate Tablets during the Treatment of Gastric Stromal Tumor
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 463-465.
|
| [15] |
ZENG Ji, ZHANG Jinke, WANG Li, CHEN Jun, MENG Xudong, NING Jing, HUANG Cheng.
One Case of Rash Caused by Apalutamide Combined with Goserelin
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 472-474.
|
